Yatin Suneja
Stock Analyst at Guggenheim
(2.18)
# 1,496
Out of 4,414 analysts
82
Total ratings
42.47%
Success rate
-6.4%
Average return
Main Sectors:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $164 → $170 | $142.67 | +19.16% | 2 | May 2, 2024 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $72 → $90 | $40.51 | +122.19% | 3 | Feb 27, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $110 → $125 | $73.86 | +69.24% | 7 | Feb 21, 2024 | |
| LBPH Longboard Pharmaceuticals | Maintains: Buy | $16 → $32 | $22.63 | +41.41% | 3 | Jan 2, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $17 → $16 | $11.28 | +41.91% | 2 | Nov 15, 2023 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $70 → $77 | $43.16 | +78.41% | 3 | Nov 15, 2023 | |
| TRML Tourmaline Bio | Initiates: Buy | $50 | $16.11 | +210.46% | 1 | Oct 31, 2023 | |
| NMRA Neumora Therapeutics | Initiates: Buy | $22 | $9.01 | +144.17% | 1 | Oct 10, 2023 | |
| SEEL Seelos Therapeutics | Downgrades: Neutral | n/a | $0.32 | - | 3 | Sep 22, 2023 | |
| IMVT Immunovant | Reiterates: Buy | $32 | $28.53 | +12.16% | 5 | Sep 22, 2023 | |
| CABA Cabaletta Bio | Reiterates: Buy | $34 | $12.54 | +171.13% | 2 | Aug 14, 2023 | |
| ARGX argenx SE | Maintains: Buy | $545 → $590 | $390.05 | +51.26% | 3 | Jul 28, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $935 → $900 | $935.81 | -3.83% | 3 | Jul 17, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Neutral | n/a | $2.56 | - | 3 | Jul 17, 2023 | |
| ZURA Zura Bio | Initiates: Buy | $20 | $4.34 | +360.83% | 1 | Jun 22, 2023 | |
| XENE Xenon Pharmaceuticals | Reiterates: Buy | $49 | $42.79 | +14.53% | 2 | Jun 15, 2023 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Buy | $52 → $55 | $19.04 | +188.87% | 2 | May 18, 2023 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $12 → $14 | $7.48 | +87.17% | 3 | May 17, 2023 | |
| ANAB AnaptysBio | Maintains: Buy | $44 → $45 | $26.44 | +70.20% | 5 | May 12, 2023 | |
| BIIB Biogen | Upgrades: Buy | $270 → $350 | $214.18 | +63.41% | 3 | May 1, 2023 | |
| IFRX InflaRx | Upgrades: Buy | $8 | $1.37 | +483.94% | 2 | Apr 5, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $55 → $48 | $8.07 | +494.80% | 2 | Mar 15, 2023 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $22 | $17.31 | +27.13% | 5 | Jan 3, 2023 | |
| SAGE Sage Therapeutics | Downgrades: Neutral | n/a | $13.05 | - | 4 | Jan 3, 2023 | |
| SRZN Surrozen | Downgrades: Neutral | n/a | $10.40 | - | 2 | Nov 18, 2022 | |
| VIGL Vigil Neuroscience | Maintains: Buy | $22 → $19 | $2.61 | +629.37% | 1 | Nov 11, 2022 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $42 → $30 | $9.59 | +212.83% | 2 | Nov 11, 2022 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | n/a | $3.78 | - | 3 | Oct 14, 2022 | |
| BLCO Bausch + Lomb | Initiates: Buy | $24 | $13.69 | +75.31% | 1 | May 31, 2022 | |
| ELYM Eliem Therapeutics | Downgrades: Neutral | n/a | $8.37 | - | 2 | Apr 26, 2022 | |
| VRNA Verona Pharma | Initiates: Buy | n/a | $15.84 | - | 1 | May 22, 2017 |
Neurocrine Biosciences
May 2, 2024
Maintains: Buy
Price Target: $164 → $170
Current: $142.67
Upside: +19.16%
Celldex Therapeutics
Feb 27, 2024
Maintains: Buy
Price Target: $72 → $90
Current: $40.51
Upside: +122.19%
Axsome Therapeutics
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $125
Current: $73.86
Upside: +69.24%
Longboard Pharmaceuticals
Jan 2, 2024
Maintains: Buy
Price Target: $16 → $32
Current: $22.63
Upside: +41.41%
Roivant Sciences
Nov 15, 2023
Maintains: Buy
Price Target: $17 → $16
Current: $11.28
Upside: +41.91%
MoonLake Immunotherapeutics
Nov 15, 2023
Maintains: Buy
Price Target: $70 → $77
Current: $43.16
Upside: +78.41%
Tourmaline Bio
Oct 31, 2023
Initiates: Buy
Price Target: $50
Current: $16.11
Upside: +210.46%
Neumora Therapeutics
Oct 10, 2023
Initiates: Buy
Price Target: $22
Current: $9.01
Upside: +144.17%
Seelos Therapeutics
Sep 22, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.32
Upside: -
Immunovant
Sep 22, 2023
Reiterates: Buy
Price Target: $32
Current: $28.53
Upside: +12.16%
Cabaletta Bio
Aug 14, 2023
Reiterates: Buy
Price Target: $34
Current: $12.54
Upside: +171.13%
argenx SE
Jul 28, 2023
Maintains: Buy
Price Target: $545 → $590
Current: $390.05
Upside: +51.26%
Regeneron Pharmaceuticals
Jul 17, 2023
Maintains: Buy
Price Target: $935 → $900
Current: $935.81
Upside: -3.83%
BioXcel Therapeutics
Jul 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.56
Upside: -
Zura Bio
Jun 22, 2023
Initiates: Buy
Price Target: $20
Current: $4.34
Upside: +360.83%
Xenon Pharmaceuticals
Jun 15, 2023
Reiterates: Buy
Price Target: $49
Current: $42.79
Upside: +14.53%
EyePoint Pharmaceuticals
May 18, 2023
Maintains: Buy
Price Target: $52 → $55
Current: $19.04
Upside: +188.87%
Larimar Therapeutics
May 17, 2023
Maintains: Buy
Price Target: $12 → $14
Current: $7.48
Upside: +87.17%
AnaptysBio
May 12, 2023
Maintains: Buy
Price Target: $44 → $45
Current: $26.44
Upside: +70.20%
Biogen
May 1, 2023
Upgrades: Buy
Price Target: $270 → $350
Current: $214.18
Upside: +63.41%
InflaRx
Apr 5, 2023
Upgrades: Buy
Price Target: $8
Current: $1.37
Upside: +483.94%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $55 → $48
Current: $8.07
Upside: +494.80%
ACADIA Pharmaceuticals
Jan 3, 2023
Upgrades: Buy
Price Target: $22
Current: $17.31
Upside: +27.13%
Sage Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $13.05
Upside: -
Surrozen
Nov 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $10.40
Upside: -
Vigil Neuroscience
Nov 11, 2022
Maintains: Buy
Price Target: $22 → $19
Current: $2.61
Upside: +629.37%
Phathom Pharmaceuticals
Nov 11, 2022
Maintains: Buy
Price Target: $42 → $30
Current: $9.59
Upside: +212.83%
Relmada Therapeutics
Oct 14, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.78
Upside: -
Bausch + Lomb
May 31, 2022
Initiates: Buy
Price Target: $24
Current: $13.69
Upside: +75.31%
Eliem Therapeutics
Apr 26, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.37
Upside: -
Verona Pharma
May 22, 2017
Initiates: Buy
Price Target: n/a
Current: $15.84
Upside: -